NASDAQ:GBIO

Generation Bio (GBIO) Stock Forecast, Price & News

$3.76

-0.01 (-0.27%)

(As of 01:21 PM ET)

Compare

Today's Range: $3.73
▼
$4.07
50-Day Range: $3.65
▼
$5.36
52-Week Range: $3.15
▼
$7.35

Volume: 13,362 shs
Average Volume: 266,222 shs
Market Capitalization: $247.90 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.05

Generation Bio MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 139.3% Upside
$9.05 Price Target
Short Interest: Bearish
4.21% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.93
Based on 2 Articles This Week
Insider Trading: Selling Shares
$31,846 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.05) to ($1.75) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

299th out of 970 stocks

Biotechnology Industry

2nd out of 14 stocks

3.3

Analyst's Opinion

Consensus Rating
Generation Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.05, Generation Bio has a forecasted upside of 139.3% from its current price of $3.78.
Amount of Analyst Coverage
Generation Bio has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
4.21% of the float of Generation Bio has been sold short.
Short Interest Ratio / Days to Cover
Generation Bio has a short interest ratio ("days to cover") of 15.6, which indicates bearish sentiment.
Change versus previous month
Short interest in Generation Bio has recently increased by 3.02%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Generation Bio does not currently pay a dividend.
Dividend Growth
Generation Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GBIO.

3.3

News and Social Media Coverage

News Sentiment
Generation Bio has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.67 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Generation Bio this week, compared to 1 article on an average week.
Search Interest
3 people have searched for GBIO on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Generation Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Generation Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $31,846.00 in company stock.
Percentage Held by Insiders
20.80% of the stock of Generation Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.81% of the stock of Generation Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Generation Bio are expected to grow in the coming year, from ($2.05) to ($1.75) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Generation Bio is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Generation Bio is -1.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Generation Bio has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Generation Bio (NASDAQ:GBIO) Stock

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

GBIO Price History

30 days | 90 days | 365 days | Advanced Chart

GBIO Stock News Headlines

September 27, 2023 | markets.businessinsider.com

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Generation Bio (GBIO), Teladoc (TDOC) and Edwards Lifesciences (EW)

September 19, 2023 | finance.yahoo.com

Generation Bio to Present at the Jefferies Cell & Genetic Medicine Summit

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

September 18, 2023 | finance.yahoo.com

We're Not Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn

August 16, 2023 | msn.com

JP Morgan Maintains Generation Bio (GBIO) Neutral Recommendation

August 7, 2023 | msn.com

Generation Bio: Novel But Preclinical, Interesting But Without Data

August 7, 2023 | finanznachrichten.de

Generation Bio Co.: Generation Bio Reports Second Quarter 2023 Financial Results

August 3, 2023 | msn.com

Wedbush Reiterates Generation Bio (GBIO) Outperform Recommendation

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

August 3, 2023 | finance.yahoo.com

Insider Buyers Lose US$80k As Generation Bio Sheds US$37m

August 3, 2023 | benzinga.com

Generation Bio Reports Second Quarter 2023 Financial Results

August 3, 2023 | markets.businessinsider.com

JMP Securities Sticks to Its Buy Rating for Generation Bio (GBIO)

August 3, 2023 | finance.yahoo.com

Generation Bio to Present at the Canaccord Genuity 43rd Annual Growth Conference

May 31, 2023 | finance.yahoo.com

Generation Bio to Present at the 2023 Jefferies Healthcare Conference

May 12, 2023 | markets.businessinsider.com

JMP Securities Keeps Their Buy Rating on Generation Bio (GBIO)

May 11, 2023 | finanznachrichten.de

Generation Bio Co.: Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

May 11, 2023 | markets.businessinsider.com

Where Generation Bio Stands With Analysts

May 11, 2023 | finance.yahoo.com

Generation Bio Co. (GBIO) Reports Q1 Loss, Misses Revenue Estimates

May 10, 2023 | finance.yahoo.com

Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

April 20, 2023 | msn.com

Needham Reiterates Generation Bio (GBIO) Buy Recommendation

April 19, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Generation Bio

April 11, 2023 | finance.yahoo.com

Generation Bio to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 10, 2023 | finance.yahoo.com

Here's Why We're Not At All Concerned With Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

April 5, 2023 | finance.yahoo.com

Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

March 24, 2023 | finance.yahoo.com

Moderna (MRNA) Inks Genetic Medicines Deal With Generation Bio

March 24, 2023 | benzinga.com

Why Generation Bio Shares Are Trading Higher Today

March 23, 2023 | markets.businessinsider.com

Needham Remains a Buy on Generation Bio (GBIO)

See More Headlines

Receive GBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Generation Bio and its competitors with MarketBeat's FREE daily newsletter.

GBIO Company Calendar

Last Earnings: 8/02/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GBIO
CUSIP: N/A
CIK: 1733294
Web: generationbio.com
Phone: 617-655-7500
Fax: N/A
Employees: 150
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.05
High Stock Price Forecast: $14.00
Low Stock Price Forecast: $2.23
Forecasted Upside/Downside: +139.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-136,640,000.00
Net Margins: N/A
Pretax Margin: -14,417.16%
Return on Equity: -45.12%
Return on Assets: -31.42%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 12.11
Quick Ratio: 12.11

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $4.75 per share
Price / Book: 0.80

Miscellaneous

Outstanding Shares: 65,930,000
Free Float: 52,216,000
Market Cap: $249.22 million
Optionable: Not Optionable
Beta: 2.22

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Cameron Geoffrey McDonough M.D. (Age 53)
Pres, CEO & Director
Comp: $939.09k

Dr. Matthew Norkunas M.B.A. (Age 45)
M.D., Chief Financial Officer
Comp: $611.11k

Dr. Matthew Stanton Ph.D. (Age 50)
Chief Scientific Officer
Comp: $654.83k

Dr. Douglas Kerr M.B.A. (Age 56)
M.D., Ph.D., Chief Medical Officer
Comp: $659.1k

Dr. Tracy Zimmermann Ph.D. (Age 53)
Chief Devel. Officer
Comp: $622.74k

Dr. Mark D. Angelino Ph.D. (Age 50)
Co-Founder

Dr. Robert Kotin Ph.D. (Age 67)
Co-Founder

Ms. Antoinette Paone M.B.A. (Age 45)
M.S., Chief Operating Officer

Ms. Yalonda Howze J.D. (Age 51)
Chief Legal Officer & Sec.

Ms. Jasmin Tower
Sr. VP of People & Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GBIO Stock - Frequently Asked Questions

Should I buy or sell Generation Bio stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Generation Bio in the last twelve months. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" GBIO shares.
View GBIO analyst ratings or view top-rated stocks.
What is Generation Bio's stock price forecast for 2023?: 6 Wall Street analysts have issued 1-year price targets for Generation Bio's shares. Their GBIO share price forecasts range from $2.23 to $14.00. On average, they predict the company's stock price to reach $9.05 in the next twelve months. This suggests a possible upside of 139.3% from the stock's current price.
View analysts price targets for GBIO or view top-rated stocks among Wall Street analysts.
How have GBIO shares performed in 2023?: Generation Bio's stock was trading at $3.93 on January 1st, 2023. Since then, GBIO shares have decreased by 3.8% and is now trading at $3.78.
View the best growth stocks for 2023 here.
When is Generation Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our GBIO earnings forecast.
How were Generation Bio's earnings last quarter?: Generation Bio Co. (NASDAQ:GBIO) announced its earnings results on Wednesday, August, 2nd. The company reported ($0.47) earnings per share for the quarter, topping analysts' consensus estimates of ($0.49) by $0.02. The business earned $0.88 million during the quarter, compared to analyst estimates of $7.50 million.
What other stocks do shareholders of Generation Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Generation Bio investors own include DocuSign (DOCU), NVIDIA (NVDA), Overstock.com (OSTK), Boeing (BA), Pure Storage (PSTG), Mastercard (MA), QUALCOMM (QCOM), Riot Platforms (RIOT), Twilio (TWLO) and Enphase Energy (ENPH).

When did Generation Bio IPO?: (GBIO) raised $126 million in an initial public offering (IPO) on Friday, June 12th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Generation Bio's stock symbol?: Generation Bio trades on the NASDAQ under the ticker symbol "GBIO."
How do I buy shares of Generation Bio?: Shares of GBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Generation Bio's stock price today?: One share of GBIO stock can currently be purchased for approximately $3.78.
How much money does Generation Bio make?: Generation Bio (NASDAQ:GBIO) has a market capitalization of $249.22 million. The company earns $-136,640,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.
How many employees does Generation Bio have?: The company employs 150 workers across the globe.
How can I contact Generation Bio?: Generation Bio's mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The official website for the company is generationbio.com. The company can be reached via phone at 617-655-7500 or via email at investors@generationbio.com.

This page (NASDAQ:GBIO) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial